Immuneering (IMRX) Equity Average (2020 - 2024)
Immuneering (IMRX) has 5 years of Equity Average data on record, last reported at $62.0 million in Q3 2024.
- For Q3 2024, Equity Average fell 43.4% year-over-year to $62.0 million; the TTM value through Sep 2024 reached $62.0 million, down 43.4%, while the annual FY2023 figure was $100.2 million, 24.6% down from the prior year.
- Equity Average reached $62.0 million in Q3 2024 per IMRX's latest filing, down from $72.5 million in the prior quarter.
- Across five years, Equity Average topped out at $157.1 million in Q4 2021 and bottomed at -$31.9 million in Q2 2021.
- Average Equity Average over 5 years is $76.2 million, with a median of $97.3 million recorded in 2023.
- Peak YoY movement for Equity Average: skyrocketed 898.79% in 2021, then plummeted 43.4% in 2024.
- A 5-year view of Equity Average shows it stood at -$19.7 million in 2020, then surged by 898.79% to $157.1 million in 2021, then decreased by 26.26% to $115.9 million in 2022, then decreased by 16.03% to $97.3 million in 2023, then crashed by 36.26% to $62.0 million in 2024.
- Per Business Quant database, its latest 3 readings for Equity Average were $62.0 million in Q3 2024, $72.5 million in Q2 2024, and $84.6 million in Q1 2024.